MedPath

Het verschil tussen een tijdelijke en een op maat gemaakte uitneembare beugel voor de behandeling van slaapapneu

Conditions
Obstructive Sleep ApneaMandibular Advancement Device
Registration Number
NL-OMON28622
Lead Sponsor
Academic Center Dentistry Amsterdam (ACTA)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
58
Inclusion Criteria

•>18 years of age

•Diagnosis of OSA confirmed by a PSG (AHI ≥ 5)

Exclusion Criteria

Medical and psychological criteria:

•Reversible morphological upper airway abnormalities (e.g. enlarged tonsils)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
•PSG parameters: Baseline AHI, AHI after 12 weeks follow-up with either MyTAP or TAP1 (total AHI, supine AHI, non-supine AHI and ODI <br /><br>•WristOx parameters: ODI<br /><br>•DISE outcomes: by using the VOTE classification with and without jaw thrust and MyTAP <br /><br><br /><br>Treatment with MyTAP or TAP1 therapy is listed as successful if the AHI reduction either is <5 or showed a 50% reduction from the baseline AHI, with an AHI of at least <10 per hour in a patient without subjective OSA symptoms while using therapy. <br>
Secondary Outcome Measures
NameTimeMethod
•Questionnaires: Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Short form Survey (RAND36) at baseline, 12 and 25 weeks of follow-up<br /><br>•Mandibular advancement: percentage of maximal protrusion after 12 weeks of treatment with MyTAP and after 12 weeks of treatment with a custom-made MAD <br /><br>•Compliance and treatment satisfaction: therapy use in hours/night and nights/week, therapy evaluation <br /><br>•Adverse Events: possible temporary side effects on short term such as: Hypo or hypersalivation, Sensitive dentition or gums, Sensitive joints or muscles
© Copyright 2025. All Rights Reserved by MedPath